X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DIVIS LABORATORIES VENUS REMEDIES/
DIVIS LABORATORIES
 
P/E (TTM) x -4.1 35.9 - View Chart
P/BV x 0.2 7.0 2.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   DIVIS LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
DIVIS LABORATORIES
Mar-18
VENUS REMEDIES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1261,142 11.0%   
Low Rs61533 11.5%   
Sales per share (Unadj.) Rs301.8146.6 205.9%  
Earnings per share (Unadj.) Rs-24.933.0 -75.3%  
Cash flow per share (Unadj.) Rs2.538.4 6.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs293.3222.8 131.6%  
Shares outstanding (eoy) m12.34265.47 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.7 5.4%   
Avg P/E ratio x-3.825.3 -14.8%  
P/CF ratio (eoy) x36.721.8 168.5%  
Price / Book Value ratio x0.33.8 8.5%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m1,154222,318 0.5%   
No. of employees `0000.910.8 8.6%   
Total wages/salary Rs m3934,561 8.6%   
Avg. sales/employee Rs Th4,026.13,616.0 111.3%   
Avg. wages/employee Rs Th425.0423.8 100.3%   
Avg. net profit/employee Rs Th-331.8814.9 -40.7%   
INCOME DATA
Net Sales Rs m3,72438,915 9.6%  
Other income Rs m231,134 2.0%   
Total revenues Rs m3,74740,049 9.4%   
Gross profit Rs m39512,617 3.1%  
Depreciation Rs m3381,425 23.7%   
Interest Rs m35413 2,663.9%   
Profit before tax Rs m-27512,313 -2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m323,543 0.9%   
Profit after tax Rs m-3078,770 -3.5%  
Gross profit margin %10.632.4 32.7%  
Effective tax rate %-11.528.8 -39.9%   
Net profit margin %-8.222.5 -36.6%  
BALANCE SHEET DATA
Current assets Rs m2,63845,351 5.8%   
Current liabilities Rs m2,3056,507 35.4%   
Net working cap to sales %8.999.8 9.0%  
Current ratio x1.17.0 16.4%  
Inventory Days Days135127 106.9%  
Debtors Days Days4695 48.7%  
Net fixed assets Rs m4,87121,160 23.0%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m3,49658,625 6.0%   
Net worth Rs m3,61959,156 6.1%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50967,832 11.1%  
Interest coverage x0.2926.8 0.0%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.6 86.5%   
Return on assets %0.612.9 4.9%  
Return on equity %-8.514.8 -57.2%  
Return on capital %1.620.8 7.6%  
Exports to sales %00-   
Imports to sales %13.921.8 63.6%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m5178,485 6.1%   
Fx inflow Rs m032,359 0.0%   
Fx outflow Rs m5179,042 5.7%   
Net fx Rs m-51723,317 -2.2%   
CASH FLOW
From Operations Rs m5147,759 6.6%  
From Investments Rs m-123-4,783 2.6%  
From Financial Activity Rs m-387-3,142 12.3%  
Net Cashflow Rs m4-166 -2.5%  

Share Holding

Indian Promoters % 32.9 52.0 63.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.5%  
FIIs % 0.6 19.0 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.2 386.0%  
Shareholders   20,121 31,796 63.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 16, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - J.B.CHEMICALS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS